Business
Posting of Circular and Notice of General Meeting
Posting of Circular and Notice of General Meeting.
About this update from Aptamer Group Plc
8 July 2025 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Posting of Circular and Notice of General Meeting Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces further to the announcement on 4 July 2025 relating to its proposed placing to raise £2.0 million (before expenses) ("Announcement"), that it has despatched the Circular and Notice of General Meeting to Shareholders. The Directors confirm they are to convene a General Meeting of the Company at 11.00 am on Thursday, 24 July 2025, at Windmill House, Innovation Way, York, YO10 5BR. The Circular and Notice of General Meeting is available on the Company's website at https://aptamergroup.com/investors/reports-and-presentations . The results of voting on all resolutions at the General Meeting will be announced via the Regulatory News Service, and the full results of the voting will be published on the Company's website as soon as practicable after the conclusion of the General Meeting. - Ends - For further information, please contact: Aptamer Group plc Dr Arron Tolley +44 (0) 1904 217 404 SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat +44 (0) 20 3368 3550 Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker +44 (0) 20 3657 0050 Northstar Communication Limited Sarah Hollins +44 (0) 113 730 3896 About Aptamer Group plc Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies. Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue. Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK. To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/